Tesamorelin vs LL-37
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone PeptidesFat Loss & Metabolic
TesamorelinImmune SupportRecovery & Repair
LL-37- Summary
- Tesamorelin is an FDA-approved synthetic GHRH analog specifically indicated for reduction of excess abdominal (visceral) fat in HIV patients with lipodystrophy. It is the only GHRH peptide with FDA approval for a fat-reduction indication and is studied off-label for metabolic syndrome and cognitive function.
- LL-37 is the only known human cathelicidin antimicrobial peptide. It kills bacteria, fungi, and viruses by disrupting their membranes, while simultaneously modulating immune responses. Used for antimicrobial protection, immune priming, and wound healing.
- Half-Life
- ~26 minutes
- Very short (~1–2 hours) in plasma due to protease degradation; topical use bypasses systemic clearance
- Admin Route
- SubQ
- SubQ, Topical, Intranasal
- Research
- —
- —
- Typical Dose
- 2 mg
- 100–300 mcg
- Frequency
- Once daily
- 2–3x per week
- Key Benefits
- FDA-approved for visceral fat reduction in HIV lipodystrophy
- Significant reduction in trunk/visceral fat (average 15–20% in trials)
- Improved triglyceride and lipid profiles
- Potential cognitive benefits and memory improvement
- Preserves lean mass while reducing fat
- Natural pulsatile GH stimulation
- Broad-spectrum antimicrobial (bacteria, fungi, viruses)
- Promotes wound healing and angiogenesis
- Immune system modulation — enhances innate immunity
- Reduces LPS-mediated endotoxemia
- Anti-biofilm activity against resistant organisms
- Promotes tissue regeneration and keratinocyte migration
- May protect against sepsis
- Side Effects
- Injection site reactions (redness, irritation)
- Arthralgia and joint pain
- Peripheral edema
- Carpal tunnel syndrome
- +2 more
- Injection site redness and irritation
- Mild inflammatory response at injection site
- Potential pro-inflammatory at high doses
- Rare: fever or flu-like symptoms at initiation
- Stacks With
- —
- —